Adderall history?

Here’s a concise history of Adderall and its place in ADHD/narcolepsy treatment:

- Origins of the stimulant class
- 1887: Amphetamine was first synthesized by Lazar Edeleanu in Germany.
- 1930s: Amphetamine-based products (notably Benzedrine) were marketed for a range of conditions, including alertness and mood. This helped establish the broader use of stimulants in medicine.

- Earlier ADHD/narcolepsy treatments
- 1950s–1960s: Dextroamphetamine (Dexedrine) and other amphetamine formulations became common for ADHD and narcolepsy, paving the way for later combination products.

- Regulatory framework
- Amphetamine and its salts are controlled substances (Schedule II in the U.S.), reflecting their potential for abuse and dependence.

- Adderall enters the scene
- 1996: FDA approves Adderall (a fixed-dose combination of four amphetamine salts) for ADHD and narcolepsy. The mix is designed to provide both immediate and sustained effects.
- Composition: Adderall contains four amphetamine salts—amphetamine aspartate monohydrate, amphetamine sulfate, dextroamphetamine sulfate, and dextroamphetamine saccharate.

- Extended-release development
- Early 2000s: Adderall XR (extended-release) is introduced, delivering both immediate- and extended-release amphetamine to cover a longer portion of the day.
- Mechanism: Adderall XR uses a multi-bead delivery system to provide a two-phase release of the active salts.

- Corporate and market evolution
- The brand’s distribution and marketing rights moved through corporate changes over the years. Shire (a major ADHD-focused company) held rights for a period, and Shire was acquired by Takeda in 2019. The Adderall brand remains a key product in the U.S. market, with generics also available.

- Generics and recent history
- Since the 2000s–2010s, generic versions of Adderall (mixed amphetamine salts) have become widely available, contributing to broader access but also to ongoing concerns about abuse and diversion.
- Adderall, like other stimulant medications, remains a Schedule II controlled substance and is subject to monitoring because of potential misuse and cardiovascular risks.

If you’d like, I can tailor this to a specific aspect (e.g., the formulation details of the four salts, the development of Adderall XR, regulatory milestones, or the history of ADHD diagnosis itself).